SARS-CoV-2 nucleocapsid protein-derived peptide-HLA complex (SARS-CoV-2 N-pHLA)

The SARS-CoV-2 nucleocapsid protein-derived peptide-HLA complex is a molecular assembly consisting of a short peptide fragment from the viral nucleocapsid (N) protein bound within the groove of a Human Leukocyte Antigen (HLA) molecule. The N protein is a highly conserved structural component of the virus responsible for packaging the viral RNA genome, and its high expression levels during infection make it a prominent source of antigens (PMID: 32859319). These complexes are presented on the surface of infected host cells, where they serve as the primary signal for recognition by the cellular arm of the immune system, specifically CD8+ cytotoxic T cells and CD4+ helper T cells (PMID: 33654090). Recognition occurs via the T-cell receptor (TCR), which triggers the release of cytotoxic granules and proinflammatory cytokines to eliminate the infected cell. In the context of drug development, these complexes are being utilized as therapeutic targets for next-generation COVID-19 treatments, including TCR-engineered T-cell (TCR-T) therapies and TCR-like monoclonal antibodies (PMID: 34659240). Because the N protein is less susceptible to the rapid mutations observed in the spike protein, targeting N-derived peptide-HLA complexes may offer more durable protection against emerging SARS-CoV-2 variants (PMID: 32887671). However, therapeutic application requires precise HLA matching (e.g., HLA-A*02:01) and careful screening to avoid cross-reactivity with human self-peptides, which could lead to autoimmune-like toxicities.

Other names

SARS-CoV-2 N-peptide-MHC complexNucleocapsid-HLA complexN-protein-derived epitope-HLA complexSARS-CoV-2 N-pHLA complex

Recognition by T-cell receptors (TCRs) or TCR-like molecules leading to targeted lysis of infected cells and cytokine release.